HC
AMPE

HNP Capital’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

HNP Capital’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,267
Closed -$200K – 304
2020
Q1 		$200K Buy
+1,267
New +$229K 0.03% 253

Other funds holding AMPE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

HNP Capital's AMPE Position: Q2 2020 in Review

HNP Capital sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2020, closing a stake of 1,267 shares — an estimated $200K sold.

HNP Capital first reported a position in AMPE in Q1 2020 and held it in 1 quarter. The position peaked at $200K in Q1 2020. 79 funds tracked by Wall St. Rank hold AMPE as of Q2 2020.

  • HNP Capital reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2020 after selling out during the quarter.
  • HNP Capital sold 1,267 Ampio Pharmaceuticals Inc. shares in Q2 2020, an estimated $200K.
  • HNP Capital first reported a position in Ampio Pharmaceuticals Inc. in Q1 2020 and held it in 1 quarter.
  • HNP Capital's Ampio Pharmaceuticals Inc. position peaked at $200K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2020.

Based on HNP Capital's 13F filing for Q2 2020, filed 6 Jul 2020.